Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kadmon Pharma has acquired Three Rivers Pharmaceuticals, a specialty drug manufacturer based in Warrendale, Pennsylvania.
Subscribe to our email newsletter
With this acquisition, Three Rivers is expected to serve as the commercial and operational cornerstone for Kadmon.
Three Rivers is known to currently market several products for the growing hepatitis C market, including Infergen (Consensus Interferon), Ribasphere (ribavirin, USP) and RibaPak (ribavirin) and also Amphotec (Amphotericin B Cholesteryl Sulfate) for the treatment of invasive aspergillosis and anastrazole for the treatment of certain cancers.
Kadmon expects to maintain the company’s Warrendale headquarters, along with its manufacturing, distribution, commercial and administrative operations.
Kadmon Pharmaceuticals CEO Samuel Waksal said that Kadmon is building a new paradigm for bringing medicines to market more rapidly and cost effectively.
"This acquisition provides us with a commercial platform from which to expand our pipeline of new therapies in oncology, infectious diseases and immunology," Waksal said.
Three Rivers Pharmaceuticals CEO Donald Kerrish said that the acquisition agreement represents a validation of their accomplishments and an exciting new chapter for the company and for their employees.